Prostac: A New Composite Score With Potential Predictive Value in Prostate Cancer.
Prostac: A New Composite Score With Potential Predictive Value in Prostate Cancer.
复制标题
DOI：
10.3389/fonc.2021.644665
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Ogunwobi OO
中科院分区：
文献类型：
--
作者：
Asante-Asamani EO;Pal G;Liu L;Ogunwobi OO
前列腺癌（PCa）是全世界男性中最常诊断的实体器官癌症。目前PCa的诊断包括使用初始前列腺特异性抗原测定，其具有高假阳性率、低特异性和低灵敏度。健康男性遭受不必要的前列腺活检的副作用，通常会导致意想不到的健康并发症。正在发现新的PCa生物标志物来解决这一未满足的需求。在这里，我们报告了基于三个最近发现的PCa生物标志物，浆细胞瘤变异易位1（PVT1）外显子4A，4B和9的综合评分（Proximity）的创建。来自基于实时定量聚合酶链（qPCR）反应的测定的拷贝数的统计分析显示这些PCa生物标志物是线性可分离的并且在PCa上皮细胞中显著过表达。我们使用支持向量机来训练监督学习算法，以生成一个分类超平面，从中开发出一个用户友好的综合得分。使用来自前列腺上皮细胞（RWPE 1）和PCa细胞（MDA PCa 2b）的数据的Proximal的交叉验证准确地分类了100%的PCa细胞。前列腺素评分的创建为其在PCa诊断中的临床试验奠定了基础。
Prostate cancer (PCa) is the most commonly diagnosed solid organ cancer in men worldwide. Current diagnosis of PCa includes use of initial prostate specific antigen assay which has a high false positive rate, low specificity, and low sensitivity. The side effects of unnecessary prostate biopsies that healthy men are subjected to, often result in unintended health complications. New PCa biomarkers are being discovered to address this unmet need. Here, we report on the creation of a composite score (Prostac) based on three recently discovered PCa biomarkers, Plasmacytoma Variant Translocation 1 (PVT1) exons 4A, 4B, and 9. Statistical analysis of copy numbers derived from a real-time quantitative polymerase chain (qPCR) reaction - based assay, showed these PCa biomarkers to be linearly separable and significantly over expressed in PCa epithelial cells. We train a supervised learning algorithm using support vector machines to generate a classification hyperplane from which a user-friendly composite score is developed. Cross validation of Prostac using data from prostate epithelial cells (RWPE1) and PCa cells (MDA PCa 2b) accurately classified 100% of PCa cells. Creation of the Prostac score lays the groundwork for clinical trial of its use in PCa diagnosis.